The DOI matches its Crossref record; 101 of the 101 references it cites were found in a registry or an index.
Combined corticosteroid and long-acting beta 2 -agonist in one inhaler versus placebo for chronic obstructive pulmonary disease
Open accessAbstract
BACKGROUND: Both long-acting beta2-agonists (LABA) and inhaled corticosteroids (ICS) have been recommended in guidelines for the treatment of chronic obstructive pulmonary disease (COPD). Their coadministration in a combination inhaler may facilitate adherence to medication regimens and improve efficacy. OBJECTIVES: To determine the efficacy and safety of combined ICS and LABA for stable COPD in comparison with placebo. SEARCH METHODS: We searched the Cochrane Airways Group Specialised Register of trials, reference lists of included studies and manufacturers' trial registries. The date of the most recent search was June 2013. SELECTION CRITERIA: We included randomised and double-blind studies of at least four weeks' duration. Eligible studies compared combined ICS and LABA preparations with placebo. DATA COLLECTION AND ANALYSIS: Two review authors independently assessed study risk of bias and extracted data. Dichotomous data were analysed as fixed-effect odds ratios (OR) or rate ratios (RR) with 95% confidence intervals (95% CI), and continuous data as mean differences with 95% confidence intervals. MAIN RESULTS: Nineteen studies met the inclusion criteria (with 10,400 participants randomly assigned, lasting between 4 and 156 weeks, mean 42 weeks). Studies used three different combined preparations (fluticasone/salmeterol, budesonide/formoterol or mometasone/formoterol). The studies were generally at low risk of bias for blinding but at unclear or high risk for attrition bias because of participant dropouts. Compared with placebo, both fluticasone/salmeterol and budesonide/formoterol reduced the rate of exacerbations. Mometasone/formoterol reduced the number of participants experiencing one or more exacerbation. Pooled analysis of the combined therapies indicated that exacerbations were less frequent when compared with placebo (Rate Ratio 0.73; 95% CI 0.69 to 0.78, 7 studies, 7495 participants); the quality of this evidence when GRADE criteria were applied was rated as moderate. Participants included in these trials had on average one or two exacerbations per year, which means that treatment with combined therapy would lead to a reduction of one exacerbation every two to four years in these individuals. An overall reduction in mortality was seen, but this outcome was dominated by the results of one study (TORCH) of fluticasone/salmeterol. Generally, deaths in the smaller, shorter studies were too few to contribute to the overall estimate. Further longer studies on budesonide/formoterol and mometasone/formoterol are required to clarify whether this is seen more widely. When a baseline risk of death of 15.2% from the placebo arm of TORCH was used, the three-year number needed to treat for an additional beneficial outcome (NNTB) with fluticasone/salmeterol to prevent one extra death was 42 (95% CI 24 to 775). All three combined treatments led to statistically significant improvement in health status measurements, although the mean differences observed are relatively small in relation to the minimum clinically important difference. Furthermore, symptoms and lung function assessments favoured combined treatments. An increase in the risk of pneumonia was noted with combined inhalers compared with placebo treatment (OR 1.62, 95% CI 1.36 to 1.94), and the quality of this evidence was rated as moderate, but no dose effect was seen. The three-year NNTH for one extra case of pneumonia was 17, based on a 12.3% risk of pneumonia in the placebo arm of TORCH. Fewer participants withdrew from the combined treatment arms for adverse events or lack of efficacy. AUTHORS' CONCLUSIONS: Combined inhaler therapy led to around a quarter fewer COPD exacerbations than were seen with placebo. A significant reduction in all-cause mortality was noted, but this outcome was dominated by one trial (TORCH), emphasising the need for further trials of longer duration. Increased risk of pneumonia is a concern; however, this did not translate into increased exacerbations, hospitalisations or deaths. Current evidence does not suggest any major differences between inhalers in terms of effects, but nor is the evidence strong enough to demonstrate that all are equivalent. To permit firmer conclusions about the effects of combined therapy, more data are needed, particularly in relation to the profile of adverse events and benefits in relation to different formulations and doses of inhaled ICS. Head-to-head comparisons are necessary to determine whether one combined inhaler is better than the others.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
Zhang, Q., Wang, C., Zheng, M., Li, Y., Li, J., Zhang, L., Shang, X., & Yan, C. (2015) · Cerebrovascular Diseases · doi:10.1159/000369778 · Cited by 11,533
GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION
PAUWELS, R. A. (1996) · Arerugī/Arerugi · doi:10.15036/arerugi.45.792 · Cited by 9,994
Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1. The Cochrane Collaboration
Higgins, J. P. T., Green, S. R., & Higgins, J. P. T. (2008) · Cited by 7,175
PAUWELS, R. A., BUIST, A. S., CALVERLEY, P. M. A., JENKINS, C. R., & HURD, S. S. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.163.5.2101039 · Cited by 6,587
Dong, Y., Hao, L., Shi, Z., Wang, G., Zhang, Z., & Han, C. (2013) · Urologia Internationalis · doi:10.1159/000351405 · Cited by 4,540
Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease
Calverley, P. M. A., Anderson, J. A., Celli, B., Ferguson, G. T., Jenkins, C., Jones, P. W., Yates, J. C., & Vestbo, J. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa063070 · Cited by 3,248
A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema
(2003) · New England Journal of Medicine · doi:10.1056/nejmoa030287 · Cited by 2,071
A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease
Tashkin, D. P., Celli, B., Senn, S., Burkhart, D., Kesten, S., Menjoge, S., & Decramer, M. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805800 · Cited by 1,604
A double‐blind, placebo‐controlled trial
Pinals, R. S., Kaplan, S. B., Lawson, J. G., & Hepburn, B. (1986) · Arthritis & Rheumatism · doi:10.1002/art.1780291202 · Cited by 1,355
(1995) · PubMed · Cited by 1,323
Calverley, P., Pauwels, R., Vestbo, J., Jones, P., Pride, N., Gulsvik, A., Anderson, J., & Maden, C. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12459-2 · Cited by 1,221
Qaseem, A., Wilt, T. J., Weinberger, S. E., Hanania, N. A., Criner, G., van der Molen, T., Marciniuk, D. D., Denberg, T., Schünemann, H., Wedzicha, W., et al. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-3-201108020-00008 · Cited by 1,087
Pauwels, R. A., Löfdahl, C.-G., Laitinen, L. A., Schouten, J. P., Postma, D. S., Pride, N. B., & Ohlsson, S. V. (1999) · New England Journal of Medicine · doi:10.1056/nejm199906243402503 · Cited by 1,074
Toward a Consensus Definition for COPD Exacerbations
Rodriguez-Roisin, R. (2000) · Chest · doi:10.1378/chest.117.5_suppl_2.398s · Cited by 969
Szafranski, W., Cukier, A., Ramirez, A., Menga, G., Sansores, R., Nahabedian, S., Peterson, S., & Olsson, H. (2003) · European Respiratory Journal · doi:10.1183/09031936.03.00031402 · Cited by 887
St. George's Respiratory Questionnaire: MCID
Jones, P. W. (2005) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.1081/copd-200050513 · Cited by 855
(2000) · New England Journal of Medicine · doi:10.1056/nejm200012283432601 · Cited by 830
Vestbo, J., Søorensen, T., Lange, P., Brix, A., Torre, P., & Viskum, K. (1999) · The Lancet · doi:10.1016/s0140-6736(98)10019-3 · Cited by 816
Immunologic Aspects of Chronic Obstructive Pulmonary Disease
Cosio, M. G., Saetta, M., & Agusti, A. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0804752 · Cited by 815
Celli, B. R., Thomas, N. E., Anderson, J. A., Ferguson, G. T., Jenkins, C. R., Jones, P. W., Vestbo, J., Knobil, K., Yates, J. C., & Calverley, P. M. A. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200712-1869oc · Cited by 748
Maintenance therapy with budesonide and formoterol in chronicobstructive pulmonary disease
Calverley, P. M., Boonsawat, W., Cseke, Z., Zhong, N., Peterson, S., & Olsson, H. (2003) · European Respiratory Journal · doi:10.1183/09031936.03.00027003 · Cited by 730
Aaron, S. D., Vandemheen, K. L., Fergusson, D., Maltais, F., Bourbeau, J., Goldstein, R., Balter, M., O'Donnell, D., McIvor, A., Sharma, S., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-8-200704170-00152 · Cited by 649
Interpreting thresholds for a clinically significant change in health status in asthma and COPD
Jones, P. W. (2002) · European Respiratory Journal · doi:10.1183/09031936.02.00063702 · Cited by 585
McGarvey, L. P., John, M., Anderson, J. A., Zvarich, M., & Wise, R. A. (2007) · Thorax · doi:10.1136/thx.2006.072348 · Cited by 561
Minimal Clinically Important Differences in COPD Lung Function
Donohue, J. F. (2005) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.1081/copd-200053377 · Cited by 529
Inhaled corticosteroids for stable chronic obstructive pulmonary disease
Yang, I. A., Clarke, M. S., Sim, E. H., & Fong, K. M. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002991.pub3 · Cited by 523
Adherence to inhaled therapy, mortality and hospital admission in COPD
Vestbo, J., Anderson, J. A., Calverley, P. M. A., Celli, B., Ferguson, G. T., Jenkins, C., Knobil, K., Willits, L. R., Yates, J. C., & Jones, P. W. (2009) · Thorax · doi:10.1136/thx.2009.113662 · Cited by 516
Bronchodilator reversibility testing in chronic obstructive pulmonary disease
Calverley, P. M. A. (2003) · Thorax · doi:10.1136/thorax.58.8.659 · Cited by 512
Mahler, D. A., Wire, P., Horstman, D., Chang, C.-N., Yates, J., Fischer, T., & Shah, T. (2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2112055 · Cited by 495
Quality of life changes in COPD patients treated with salmeterol.
Jones, P. W., & Bosh, T. K. (1997) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.155.4.9105068 · Cited by 494
ITO, K., LIM, S., CARAMORI, G., CHUNG, K. F., BARNES, P. J., & ADCOCK, I. M. (2001) · The FASEB Journal · doi:10.1096/fj.00-0432fje · Cited by 481
Crim, C., Calverley, P. M. A., Anderson, J. A., Celli, B., Ferguson, G. T., Jenkins, C., Jones, P. W., Willits, L. R., Yates, J. C., & Vestbo, J. (2009) · European Respiratory Journal · doi:10.1183/09031936.00193908 · Cited by 432
Qaseem, A., Snow, V., Shekelle, P., Sherif, K., Wilt, T. J., Weinberger, S., Owens, D. K., & for the Clinical Efficacy Assessment Subcommittee of the American College of Physicians* (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-9-200711060-00008 · Cited by 424
Welte, T., Miravitlles, M., Hernandez, P., Eriksson, G., Peterson, S., Polanowski, T., & Kessler, R. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200904-0492oc · Cited by 408
Ernst, P., Gonzalez, A. V., Brassard, P., & Suissa, S. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200611-1630oc · Cited by 389
Inhaled Formoterol Dry Powder Versus Ipratropium Bromide in Chronic Obstructive Pulmonary Disease
DAHL, R., GREEFHORST, L. A. P. M., NOWAK, D., NONIKOV, V., BYRNE, A. M., THOMSON, M. H., TILL, D., & DELLA CIOPPA, G. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.5.2007006 · Cited by 358
Jenkins, C. R., Jones, P. W., Calverley, P. M., Celli, B., Anderson, J. A., Ferguson, G. T., Yates, J. C., Willits, L. R., & Vestbo, J. (2009) · Respiratory Research · doi:10.1186/1465-9921-10-59 · Cited by 345
Hanania, N. A., Darken, P., Horstman, D., Reisner, C., Lee, B., Davis, S., & Shah, T. (2003) · Chest · doi:10.1378/chest.124.3.834 · Cited by 327
Kardos, P., Wencker, M., Glaab, T., & Vogelmeier, C. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200602-244oc · Cited by 314
Soriano, J. B., Vestbo, J., Pride, N. B., Kiri, V., Maden, C., & Maier, W. C. (2002) · European Respiratory Journal · doi:10.1183/09031936.02.00301302 · Cited by 286
An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD)
Boyd, G., Morice, A., Pounsford, J., Siebert, M., Peslis, N., & Crawford, C. (1997) · European Respiratory Journal · doi:10.1183/09031936.97.10040815 · Cited by 269
Prevalence and Progression of Osteoporosis in Patients With COPD
Ferguson, G. T., Calverley, P. M. A., Anderson, J. A., Jenkins, C. R., Jones, P. W., Willits, L. R., Yates, J. C., Vestbo, J., & Celli, B. (2009) · Chest · doi:10.1378/chest.08-3016 · Cited by 265
Nannini, L. J., Lasserson, T. J., & Poole, P. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006829.pub2 · Cited by 264
Self-citationAntiinflammatory Effects of Salmeterol/Fluticasone Propionate in Chronic Obstructive Lung Disease
Barnes, N. C., Qiu, Y.-S., Pavord, I. D., Parker, D., Davis, P. A., Zhu, J., Johnson, M., Thomson, N. C., & Jeffery, P. K. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200508-1321oc · Cited by 253
Rossi, A., Kristufek, P., Levine, B. E., Thomson, M. H., Till, D., Kottakis, J., & Della Cioppa, G. (2002) · Chest · doi:10.1378/chest.121.4.1058 · Cited by 250
Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study
Jenkins, C. R., Celli, B., Anderson, J. A., Ferguson, G. T., Jones, P. W., Vestbo, J., Yates, J. C., & Calverley, P. M. A. (2012) · European Respiratory Journal · doi:10.1183/09031936.00194610 · Cited by 235
Effect of Fluticasone Propionate/Salmeterol on Lung Hyperinflation and Exercise Endurance in COPD
O'Donnell, D. E., Sciurba, F., Celli, B., Mahler, D. A., Webb, K. A., Kalberg, C. J., & Knobil, K. (2006) · Chest · doi:10.1378/chest.130.3.647 · Cited by 233
The TORCH (TOwards a Revolution in COPD Health) survival study protocol: Fig. 1.—
The TORCH Study Group (2004) · European Respiratory Journal · doi:10.1183/09031936.04.00120603 · Cited by 224
Sutherland, E. R. (2003) · Thorax · doi:10.1136/thorax.58.11.937 · Cited by 220
Sin, D. D., Man, S. F. P., Marciniuk, D. D., Ford, G., FitzGerald, M., Wong, E., York, E., Mainra, R. R., Ramesh, W., Melenka, L. S., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200709-1356oc · Cited by 212
Cardiovascular events in patients with COPD: TORCH Study results
Calverley, P. M. A., Anderson, J. A., Celli, B., Ferguson, G. T., Jenkins, C., Jones, P. W., Crim, C., Willits, L. R., Yates, J. C., Vestbo, J., et al. (2010) · Thorax · doi:10.1136/thx.2010.136077 · Cited by 207
Tashkin, D. P., Rennard, S. I., Martin, P., Ramachandran, S., Martin, U. J., Silkoff, P. E., & Goldman, M. (2008) · Drugs · doi:10.2165/00003495-200868140-00004 · Cited by 202
Lapperre, T. S., Snoeck-Stroband, J. B., Gosman, M. M. E., Jansen, D. F., van Schadewijk, A., Thiadens, H. A., Vonk, J. M., Boezen, H. M., ten Hacken, N. H. T., Sont, J. K., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-8-200910200-00004 · Cited by 189
Celli, B., Vestbo, J., Jenkins, C. R., Jones, P. W., Ferguson, G. T., Calverley, P. M. A., Yates, J. C., Anderson, J. A., Willits, L. R., & Wise, R. A. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201004-0665oc · Cited by 186
Ducharme, F. M., Ni Chroinin, M., Greenstone, I., & Lasserson, T. J. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005535.pub2 · Cited by 185
Rennard, S. I., Tashkin, D. P., McElhattan, J., Goldman, M., Ramachandran, S., Martin, U. J., & Silkoff, P. E. (2009) · Drugs · doi:10.2165/00003495-200969050-00004 · Cited by 185
Lung function impairment, COPD hospitalisations and subsequent mortality
Garcia-Aymerich, J., Serra Pons, I., Mannino, D. M., Maas, A. K., Miller, D. P., & Davis, K. J. (2011) · Thorax · doi:10.1136/thx.2010.152876 · Cited by 183
Pedersen, B., Dahl, R., Karlström, R., Peterson, C. G. B., & Venge, P. (1996) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.153.5.8630596 · Cited by 182
Inhaled corticosteroids for stable chronic obstructive pulmonary disease
Yang, I. A., Fong, K. M., Sim, E., Black, P., & Lasserson, T. J. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002991.pub2 · Cited by 153
Burge, P. S. (2003) · Thorax · doi:10.1136/thorax.58.8.654 · Cited by 153
Bourbeau, J., Christodoulopoulos, P., Maltais, F., Yamauchi, Y., Olivenstein, R., & Hamid, Q. A. (2007) · Thorax · doi:10.1136/thx.2006.071068 · Cited by 149
Dong, Y., Lin, H.-H., Shau, W., Wu, Y., Chang, C., & Lai, M. (2012) · Thorax · doi:10.1136/thoraxjnl-2012-201926 · Cited by 140
Suissa, S. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200508-1338pp · Cited by 136
Spencer, M., Briggs, A. H., Grossman, R. F., & Rance, L. (2005) · PharmacoEconomics · doi:10.2165/00019053-200523060-00008 · Cited by 132
Chróinín, M. N., Greenstone, I. I., Ducharme, F. M., Masse, V., & Danish, A. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005535 · Cited by 128
The Breathlessness, Cough, and Sputum Scale
Leidy, N. K., Rennard, S. I., Schmier, J. K., Jones, M. K. C., & Goldman, M. H. (2003) · CHEST Journal · doi:10.1378/chest.124.6.2182 · Cited by 122
Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease
Appleton, S., Poole, P., Smith, B. J., Veale, A., Lasserson, T. J., Chan, M. M. K., & Cates, C. J. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001104.pub2 · Cited by 119
Self-citationRelationship between respiratory symptoms and medical treatment in exacerbations of COPD
Calverley, P. M. A., Pauwels, R., Lofdahl, C., Svensson, K., Higenbottam, T., Carlsson, L., & Ståhl, E. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00143404 · Cited by 109
Walters, E. H., Gibson, P. G., Lasserson, T. J., & Walters, J. A. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001385.pub2 · Cited by 105
Nannini, L. J., Poole, P., Milan, S. J., & Kesterton, A. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006826.pub2 · Cited by 103
Self-citationJung, K. S., Park, H. Y., Park, S. Y., Kim, S. K., Kim, Y., Shim, J.-J., Moon, H. S., Lee, K. H., Yoo, J.-H., & Lee, S. (2011) · Respiratory Medicine · doi:10.1016/j.rmed.2011.09.004 · Cited by 102
Bronchodilator Reversibility in COPD
Hanania, N. A., Celli, B. R., Donohue, J. F., & Martin, U. J. (2011) · CHEST Journal · doi:10.1378/chest.10-2974 · Cited by 102
Nannini, L. J., Cates, C. J., Lasserson, T., & Poole, P. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003794.pub2 · Cited by 94
Self-citationRojas, M. X., Morales, O. M. G., Dennis, R., & Karner, C. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008532.pub3 · Cited by 84
Chróinín, M. N., Greenstone, I. I., Lasserson, T. J., & Ducharme, F. M. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005307.pub2 · Cited by 83
Calverley, P. M. A., Anderson, J., Celli, B. R., Ferguson, G., Jenkins, C. R., Jones, P., Yates, J., & Vestbo, J. (2007) · Research Explorer (The University of Manchester) · Cited by 74
Health status in the TORCH study of COPD: treatment efficacy and other determinants of change
The TORCH investigators, Jones, P., Anderson, J. A., Calverley, P. M. A., Celli, B. R., Ferguson, G. T., Jenkins, C. R., Yates, J., Vestbo, J., & Spencer, M. D. (2011) · Respiratory Research · doi:10.1186/1465-9921-12-71 · Cited by 74
Briggs, A. H., Glick, H. A., Lozano‐Ortega, G., Spencer, M., Calverley, P. M. A., Jones, P. W., & Vestbo, J. (2009) · European Respiratory Journal · doi:10.1183/09031936.00153108 · Cited by 66
Vestbo, J. (2005) · Thorax · doi:10.1136/thx.2004.025411 · Cited by 61
Doherty, D. E., Tashkin, D. P., Kerwin, Knorr, Shekar, Banerjee, & Staudinger (2012) · International Journal of COPD · doi:10.2147/copd.s27320 · Cited by 60
Kauffman, K., Doherty, D. E., Kerwin, Matiz-Bueno, Knorr, Shekar, Banerjee, & Staudinger (2012) · International Journal of COPD · doi:10.2147/copd.s27319 · Cited by 58
Donohue, J. F., Kalberg, C. J., Emmett, A. H., Merchant, K., & Knobil, K. (2004) · Treatments in Respiratory Medicine · doi:10.2165/00151829-200403030-00005 · Cited by 54
Nannini, L. J., Cates, C. J., Lasserson, T. J., & Poole, P. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006826 · Cited by 48
Self-citationLindberg, A., Szalai, Z. Z., Pullerits, T., & Radeczky, E. (2007) · Respirology · doi:10.1111/j.1440-1843.2007.01132.x · Cited by 46
Onset of action of formoterol/budesonide in single inhaler vs. formoterol in patients with COPD
Cazzola, M., Santus, P., Marco, F. D., Carlucci, P., Mondoni, M., Matera, M. G., & Centanni, S. (2004) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2004.01.001 · Cited by 45
Karner, C., & Cates, C. J. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008532.pub2 · Cited by 41
Budesonide added to formoterol contributes to improved exercise tolerance in patients with COPD
Worth, H., Förster, K., Eriksson, G., Nihlén, U., Peterson, S., & MAGNUSSEN, H. (2010) · Respiratory Medicine · doi:10.1016/j.rmed.2010.07.006 · Cited by 40
Anti-Inflammatory Effects of Combined Budesonide/Formoterol in COPD Exacerbations
Bathoorn, E., Liesker, J. J. W., Postma, D. S., Boorsma, M., Bondesson, E., Koëter, G. H., Kauffman, H. F., van Oosterhout, A. J. M., & Kerstjens, H. A. M. (2008) · COPD Journal of Chronic Obstructive Pulmonary Disease · doi:10.1080/15412550802363360 · Cited by 39
Nannini, L. J., Lasserson, T., & Poole, P. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003794 · Cited by 36
Self-citationThe Canadian Optimal Therapy of COPD Trial: Design, Organization and Patient Recruitment
Aaron, S. D., Vandemheen, K. L., Fergusson, D. A., Fitzgerald, M., Maltais, F., Bourbeau, J., Goldstein, R. S., McIvor, A., Balter, M. S., & O’Donnell, D. E. (2004) · Canadian Respiratory Journal · doi:10.1155/2004/394710 · Cited by 31
Cukier, A., Ferreira, C. A. S., Stelmach, R., Ribeiro, M. S. M., Cortopassi, F. F., & Calverley, P. M. A. (2006) · Respiratory Medicine · doi:10.1016/j.rmed.2006.08.013 · Cited by 30
Seemungal, T., Stockley, R. A., Calverley, P. M. A., Hagan, G. W., & Wedzicha, J. A. (2007) · COPD Journal of Chronic Obstructive Pulmonary Disease · doi:10.1080/15412550701407862 · Cited by 28
Inhaled corticosteroids in COPD: quantifying risks and benefits
Cates, C. J. (2012) · Thorax · doi:10.1136/thoraxjnl-2012-202959 · Cited by 23
Sin, D. D., Man, S. P., Marciniuk, D. D., Ford, G. T., Fitzgerald, M., Wong, E. Y. L., York, E. L., Mainra, R., Ramesh, W., Melenka, L., et al. (2006) · BMC Pulmonary Medicine · doi:10.1186/1471-2466-6-3 · Cited by 21
[Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease].
Vestbo, J. (2004) · PubMed · Cited by 21
Schermer, T. R., Albers, J., Verblackt, H., et al. (2007) · Family Practice · doi:10.1093/fampra/cml076 · Cited by 16
Johnson, M. W., Agustí, A. G. N., & Barnes, N. C. (2008) · COPD Journal of Chronic Obstructive Pulmonary Disease · doi:10.1080/15412550802522924 · Cited by 9
Oba, Y., Fadila, M., Keeney, E., & Dias, S. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012620 · Cited by 2
Cited by
Vestbo, J., Hurd, S. S., Agustí, A. G., Jones, P. W., Vogelmeier, C., Anzueto, A., Barnes, P. J., Fabbri, L. M., Martinez, F. J., Nishimura, M., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201204-0596pp · Cited by 15,983
Chronic obstructive pulmonary disease
Decramer, M., Janssens, W., & Miravitlles, M. (2012) · The Lancet · doi:10.1016/s0140-6736(11)60968-9 · Cited by 972
Chronic obstructive pulmonary disease
Rabe, K. F., & Watz, H. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31222-9 · Cited by 960
O’Donnell, D. E., Aaron, S., Bourbeau, J., Hernandez, P., Marciniuk, D. D., Balter, M., Ford, G., Gervais, A., Goldstein, R., Hodder, R., et al. (2007) · Canadian Respiratory Journal · doi:10.1155/2007/830570 · Cited by 693
Vogelmeier, C. F., Criner, G. J., Martinez, F. J., Anzueto, A., Barnes, P. J., Bourbeau, J., Celli, B. R., Chen, R., Decramer, M., Fabbri, L. M., et al. (2017) · Respirology · doi:10.1111/resp.13012 · Cited by 681
Metadata
- Authors
- Nannini, L. J., Poole, P., Milan, S. J., Holmes, R., & Normansell, R.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2013-11-10
- Volume
- 2018
- Issue
- 3
- Pages
- CD003794-CD003794
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W1496026319
- Cited by
- 274
- References
- 101
- FWCI
- 25.58
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.